ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1436

The Association of Cigarette Smoking with Radiographic Progression in Psoriatic Arthritis

Fadi Kharouf1, Hernan Maldonado Ficco2, Shangyi Gao3, barry J Sheanne4, Daniel Pereira5, Richard Cook6, Vinod Chandran7 and Dafna Gladman8, 1University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 2Hospital San Antonio de Padua, Cordoba, Argentina, 3Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 4St James' Hospital, Dublin, Ireland, 5University Health Network, Toronto, ON, Canada, 6University of Waterloo, Waterloo, Canada, 7University of Toronto, Toronto, ON, Canada, 8University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: ACR Convergence 2024

Keywords: Psoriatic arthritis, radiography, Smoking

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 17, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The association between smoking and radiographic damage has been established in axial spondyloarthritis and rheumatoid arthritis, but not in psoriatic arthritis (PsA). We designed this study to investigate this relationship in PsA.

Methods: We included patients with PsA followed at our prospective observational cohort. Smoking status was evaluated from the baseline visit up until the first detection of progression of radiographic damage, defined as an increase of ≥1 point on the modified Steinbrocker score (mSS). We classified patients as non-smokers, past smokers, and current smokers. We used Cox regression analysis to determine the factors associated with the time to progression of peripheral joint damage; to account for potential collider bias, which could be introduced by uncontrolled confounding, we evaluated the following covariates at baseline only (and not longitudinally): swollen joint count (SJC), dactylitis, mSS, and abnormal erythrocyte sedimentation rate (ESR).

Results: Of 1736 patients included in the study, 952 (54.9%) were males, with a mean (standard deviation) age of 44.9 (13.3) years and PsA duration of 6.3 (8.1) years at baseline (Table 1). 906 (52.2%) were non-smokers, 211 (12.2%) were past smokers, and 311 (17.9%) were current smokers; 308 (17.7%) had missing smoking data. At baseline, 744 (52.1%) patients had erosions, with a median [interquartile range] mSS of 2.0 [0.0, 10.0]. In the multivariate Cox regression model, older age (HR 1.01, p< 0.001), shorter duration of psoriasis (HR 0.99, p=0.004), higher baseline SJC (HR 1.02, p=0.01) and mSS (HR 1.01, p< 0.001), as well as baseline dactylitis (HR 1.49, p< 0.001) and abnormal ESR (HR 1.32, p=0.004) were all associated with a shorter time to progression of joint damage (Table 2). Smoking (current and past; HR 0.74, p=0.01 and HR 0.78, p=0.046, respectively) and use of advanced therapy (biologic or targeted synthetic drugs) (HR 0.61, p=0.002) were associated with a longer time to progression of joint damage.

Conclusion: Cigarette smoking does not appear to be positively associated with the progression of peripheral joint damage in PsA. Further studies are required to confirm our findings.

Supporting image 1

Supporting image 2


Disclosures: F. Kharouf: None; H. Maldonado Ficco: None; S. Gao: None; b. Sheanne: None; D. Pereira: None; R. Cook: None; V. Chandran: AbbVie/Abbott, 1, 5, AstraZeneca, 12, Spousal employment, Bristol-Myers Squibb(BMS), 1, Eli Lilly, 1, Janssen, 1, Novartis, 1, UCB, 1; D. Gladman: AbbVie, 2, 5, Amgen, 2, 5, AstraZeneca, 2, BMS, 2, Celgene, 2, 5, Eli Lilly, 2, 5, Galapagos, 2, 5, Gilead, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Kharouf F, Maldonado Ficco H, Gao S, Sheanne b, Pereira D, Cook R, Chandran V, Gladman D. The Association of Cigarette Smoking with Radiographic Progression in Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-association-of-cigarette-smoking-with-radiographic-progression-in-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-of-cigarette-smoking-with-radiographic-progression-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology